Quisinostat

Generic Name: Quisinostat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆N_₆O_₂

CAS Number: 875320-29-9

Unique Ingredient Identifier: 9BJ85K1J8S

Background: Quisinostat has been used in trials studying the treatment of Lymphoma, Neoplasms, Myelodysplastic Syndromes, and Advanced or Refractory Leukemia.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Glycogen synthase kinase‐3 inhibition overcomes EMT-mediated resistance in EGFR-mutant NSCLC

EGFR-mutant NSCLC patients often develop resistance to EGFR-TKIs like osimertinib, partly due to EMT. This study found that GSK-3 inhibition can overcome EMT-mediated resistance by suppressing AKT signaling and inducing apoptosis, offering a potential strategy to combat osimertinib resistance in EGFR-mutant lung cancer.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy